Leukocyte count and risk of thrombosis in patients undergoing haematopoietic stem cell transplantation or intensive chemotherapy

Summary

Elevated white blood cell count has recently been established as an independent risk factor for thromboembolic events in patients with myeloproliferative syndromes. Thrombotic events occur frequently in patients with haematological malignancies undergoing intensive cytoreductive treatment. We evaluated retrospectively the association of leukocyte counts and thrombosis in three cohorts of 100 patients each undergoing autologous or allogeneic haematopoietic stem cell transplantation or chemotherapy, respectively. A total of 26 thromboembolic events were recorded, 10 in recipients of allogeneic transplants, five in autografted patients, and 11 in the chemotherapy group. Fifteen events were central venous catheter related. Non-catheter related thrombotic events were pulmonary embolism (N=5), hepatic veno-occlusive disease (N=2), deep-vein thrombosis (N=1), stroke (N=1), ovarian vein thrombosis (N=1), and left ventricular thrombosis (N=1). Hazard rates showed two peaks, a first during cytoreduction in all groups, and a second after engraftment in transplanted patients. Time-dependent multivariable Cox analysis confirmed an association of leukocytosis with development of thrombosis (hazard ratio for leukocyte count > 11G/l: 9.73, 95% confidence interval 1.98–47.9, p=0.005). The risk associated with leukocytosis was independent from C-reactive protein level. Thrombocyte count and type of treatment (allogeneic vs. autologous transplantation vs. chemotherapy) had no significant influence on thrombosis development. In three cohorts of patients undergoing intensive cytoreductive treatment for haematological malignancy, leukocyte count was strongly associated with development of thrombotic complications.

Keywords

Chemotherapy - leukocytes - stem cell transplantation - thrombosis

^* These authors contributed equally.

• References

• 1 Barbui T, Carobbio A, Rambaldi A. et al. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?. Blood 2009; 114: 759-763.
• 2 Carobbio A, Antonioli E, Guglielmelli P. et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 2008; 26: 2732-2736.
• 3 Passamonti F, Rumi E, Pascutto C. et al. Increase of leukocyte count over time predicts thrombosis in patients with low risk essential thrombocythemia. J Thromb Haemost 2009; 07: 1587-1589.
• 4 Landolfi R, Di Gennaro L, Barbui T. et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007; 109: 2446-2452.
• 5 Coller BS. Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene?. Arterioscler Thromb Vasc Biol 2005; 25: 658-670.
• 6 Khorana AA, Kuderer NM, Culakova E. et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902-4907.
• 7 Khorana AA, Francis CW, Culakova E. et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006; 24: 484-490.
• 8 Pihusch R, Salat C, Schmidt E. et al. Hemostatic complications in bone marrow transplantation: a retrospective analysis of 447 patients. Transplantation 2002; 74: 1303-1309.
• 9 Jones RJ, Lee KS, Beschorner WE. et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-783.
• 10 Glucksberg H, Storb R, Fefer A. et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
• 11 Kuter DJ. Thrombotic complications of central venous catheters in cancer patients. Oncologist 2004; 09: 207-216.
• 12 Falanga A, Marchetti M, Vignoli A. et al. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005; 33: 523-530.
• 13 Kostelijk EH, Fijnheer R, Nieuwenhuis HK. et al. Soluble P-selectin as parameter for platelet activation during storage. Thromb Haemost 1996; 76: 1086-1089.
• 14 Ridker PM, Hennekens CH, Buring JE. et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
• 15 Devaraj S, Singh U, Jialal I. The evolving role of C-reactive protein in atherothrombosis. Clin Chem 2009; 55: 229-238.
• 16 Gonsalves A, Carrier M, Wells PS. et al. Incidence of symptomatic venous thromboembolism following hematopoietic stem cell transplantation. J Thromb Haemost 2008; 06: 1468-1473.
• 17 Gerber DE, Segal JB, Levy MY. et al. The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. Blood 2008; 112: 504-510.
• 18 Monreal M, Zacharski L, Jimenez JA. et al. Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study. J Thromb Haemost 2004; 02: 1311-1315.